ARS Pharmaceuticals Inc (SPRY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown impressive revenue growth, its negative net income and EPS, coupled with bearish technical indicators and lack of positive trading signals, suggest that waiting for a more favorable entry point would be prudent.

Technical Analysis

The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral at 49.605, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 9.145, with resistance at 9.539 and support at 8.752. Overall, the technical indicators suggest a mixed to bearish trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a strong bullish sentiment in the options market. However, this is not supported by other technical or fundamental factors.

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds have significantly increased their buying activity, up 326% over the last quarter. The company has shown remarkable revenue growth, up 1471.62% YoY in Q3 2025.

Neutral/Negative Catalysts

Gross margin has dropped significantly by -20.91% YoY. No recent news or congress trading data is available to provide additional support for a positive outlook.

Financial Performance

In Q3 2025, revenue increased by 1471.62% YoY to $32.5M. However, the company remains unprofitable, with a net income of -$51.15M and an EPS of -0.52. Gross margin dropped to 74.8%, down -20.91% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for SPRY. Wall Street sentiment is unclear.

4 Analyst Rating

Wall Street analysts forecast SPRY stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.280

Low

Averages

32.5

High

Current: 9.280

Low

Averages

32.5

High

Oppenheimer

Outperform

maintain

$40 -> $35

AI Analysis

2025-11-11

Reason

Oppenheimer

Price Target

$40 -> $35

AI Analysis

2025-11-11

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on ARS Pharmaceuticals to $35 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 financials with $32.5M in revenue, beating consensus and surpassing OpCo estimates of $28.7M/$29.4M, respectively. Neffy's momentum reflects the DTC lift, back-to-school demand, and broader prescriber adoption across new epinephrine segments, with upcoming tailwinds from the virtual campaign, growing real-world evidence, and formulary adds in 2026, Oppenheimer adds.

Roth Capital

Kyle Bauser

initiated

$30

2025-11-04

Reason

Roth Capital

Kyle Bauser

Price Target

$30

2025-11-04

initiated

Reason

Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals with a Buy rating and $30 price target. The firm is anticipating significant revenue growth from the rapid adoption of the company's signature product, neffy, which is an innovative intranasal epinephrine device for Type 1 allergic reactions, including anaphylaxis, the analyst tells investors in a research note. The ability of neffy to take significant share from outdated epinephrine auto-injectors is currently underappreciated, particularly given the recent sales growth to date, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SPRY

Unlock Now

SPRY Should I Buy

SPRY Should I Buy

Should You Buy ARS Pharmaceuticals Inc (SPRY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch